Close
Digital Health & Ai Innovation summit 2026
APE 2026

FDA Clears Upgrade of Omnipod 5 Algorithm from Insulet

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

FDA Gives Clearance to Hugo RAS...

Medtronic, which is a global leader when it comes...

FDA May Scrutinize Medical Device Cybersecurity...

The scrutiny by the US Food and Drug Administration...

Recon DL Tool from GE HealthCare...

Pristina Recon DL tool from GE HealthCare which uses...

Insulet has gone ahead and secured the clearance from the US Food and Drug Administration – FDA for an algorithm advancement in its Omnipod 5 automated insulin delivery – AID system, thereby setting users up with much tighter insulin management.

Omnipod 5 goes on to integrate with consistent glucose monitoring – CGM systems, including flagship products from Dexcom as well as Abbott, to continuously roll out insulin for three days automatically, thereby regulating insulin and also preventing certain abrupt changes within the glucose levels.

The new algorithm change hence means that Omnipod 5 users are going to soon be able to shift their insulin target range from 100 mg/dl to 150 mg/dl within the 10 mg increments, a lowering of the previous 110 mg/dl to 150 mg/dl range.

It is worth noting that Insulet expects that the Omnipod 5 algorithm update is going to launch in the US in the first half of 2026. The company underscored that the new insulin target range looks to allow the healthcare providers to customize the insulin delivery more accurately so as to support either the AID users who are looking out for tighter glucose management or the ones who are looking to meet certain specific glucose objectives.

This algorithm update also goes on to mean that the users will be able to stay within automated mode, having many fewer interruptions, and that too even at the time of prolonged high glucose events. As per Insulet, this advancement is going to deliver much more robust clinical outcomes and also an increased agility for users, with fewer interruptions hurting their daily life.

Eric Benjamin, executive VP and COO of Insulet, went on to call the algorithm update the most significant advancement that has happened for the Omnipod 5 algorithm ever since the launch of the system in 2022.

He went on to add these new features go on to address the two most desired enhancements and reflect their relentless commitment when it comes to offering meaningful innovation for people living with diabetes and also the healthcare providers who go on to support them.

Latest stories

Related stories

FDA Gives Clearance to Hugo RAS System, Confirms Medtronic

Medtronic, which is a global leader when it comes...

FDA May Scrutinize Medical Device Cybersecurity More in 2026

The scrutiny by the US Food and Drug Administration...

Recon DL Tool from GE HealthCare Receives a PMA

Pristina Recon DL tool from GE HealthCare which uses...

Abbott to Acquire Cancer Test Maker for Around $21 Billion

In a recent move, Abbott has gone ahead and...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »